Comparing Scinai Immunotherapeutics (NASDAQ:SCNI) and Gain Therapeutics (NASDAQ:GANX)

Scinai Immunotherapeutics (NASDAQ:SCNI) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Earnings and Valuation

This table compares Scinai Immunotherapeutics and Gain Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31 million	0.46	-$8.31 million	($95.34)	-0.00
Gain Therapeutics	N/A	N/A	-$20.16 million	($0.50)	-2.00

Scinai Immunotherapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Scinai Immunotherapeutics and Gain Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Gain Therapeutics	N/A	-161.59%	-118.36%

Volatility and Risk

Scinai Immunotherapeutics has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Scinai Immunotherapeutics and Gain Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1	0	0	0	1.00
Gain Therapeutics	1	0	4	0	2.60

Gain Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 668.20%. Given Gain Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Scinai Immunotherapeutics.

Summary

Scinai Immunotherapeutics beats Gain Therapeutics on 8 of the 12 factors compared between the two stocks.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.